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Abstract
We conducted a search for non-chromosome 6 genes that may increase risk for rheumatoid arthritis
(RA). Our approach was to retrospectively ascertain three “extreme” subsamples from the North
American Rheumatoid Arthritis Consortium. The three subsamples are: 1) RA cases who have two
low-risk HLA-DRB1 alleles (N = 18), 2) RA cases who have two high-risk HLA-DRB1 alleles (N =1 6 3 ) ,
and 3) controls who have two low-risk HLA-DRB1 alleles (N = 652). We hypothesized that since Group
1’s RA was likely due to non-HLA related risk factors, and because Group 3, by definition, is unaffected,
comparing Group 1 with Group 2 and Group 1 with Group 3 would result in the identification of
candidate susceptibility loci located outside of the MHC region. Accordingly, we restricted our search
to the 21 non-chromosome 6 autosomes. The case-case comparison of Groups 1 and 2 resulted in the
identification of 17 SNPs with allele frequencies that differed at p < 0.0001. The case-control
comparison of Groups 1 and 3 identified 23 SNPs that differed in allele frequency at p < 0.0001. Eight of
these SNPs (rs10498105, rs2398966, rs7664880, rs7447161, rs2793471, rs2611279, rs7967594, and
rs742605) were common to both lists.
Background
Rheumatoid arthritis (RA) is a chronic inflammatory
disorder in which the articular joints are gradually
destroyed. Occasionally there is systemic involvement,
which can include pulmonary fibrosis and vasculitis in
various organs. The etiology of RA is complex, with
significant genetic and environmental components.
Among the genetic components, genes in the MHC
region on chromosome 6p21.3 are widely acknowledged
to be the major player, with the HLA-DRB1 locus as the
leading suspect [1,2]. Five alleles dramatically increase
risk (DRB1*0401, *0404, *0405, *0408,a n d*0409),
while other alleles appear to confer a moderate increase
in risk (DRB1*0101, *0102, *0104, *0105, *1001, *1402,
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alleles as H, the moderate risk alleles as M and the low-
risk alleles as L. Most of the high-risk alleles possess a
shared epitope (SE) of five amino acids at positions 70-
74 in the third hypervariable region of the DRb1chain
[3]. Genotypes consisting of alleles *0401/DRX (where
DRX denotes a non-SE allele) and *0404/DRX are
estimated to increase the relative risk of RA by 4.7-fold
and 5.0-fold, respectively, while the *0401/*0401 geno-
type carries a relative risk of 18.8 and the compound
heterozygote *0401/*0404 has a relative risk of 31.0
[4,5]. We included in the high-risk group individuals
whose genotype was reported as 4/4 or 4/*0401.
Not all persons with RA possess one or two high-risk SE
alleles, however. It is estimated that in persons of
European ancestry, approximately 30% do not carry an
SE-encoding allele [2]. In the data made available to the
Genetic Analysis Workshop 16 participants, the percen-
tage of cases carrying two low risk DRB1 a l l e l e si sm u c h
smaller than 30%. We hypothesize that RA cases with
two non-SE encoding DRB1 alleles constitute a subgroup
of patients that are enriched for other susceptibility
alleles located elsewhere in the genome. Accordingly, we
undertook a genome-wide association (GWA) analysis
that compares single-nucleotide polymorphism (SNP)
allele frequencies in two groups of cases-those whose
DRB1 genotype contains two high-risk alleles (HH) and
those whose DRB1 genotype contains two low-risk
alleles (LL)-and one group of controls whose DRB1
genotype also consists of two LL alleles.
Methods
Table 1 reports the distribution of HLA-DRB1 genotypes in
cases and controls from the North American Rheumatoid
Arthritis Consortium (NARAC). There were an additional
69 cases and a single control for whom DRB1 genotypes
were not available. Table 1 underscores the substantial
difference between cases and controls at DRB1 (c
2 = 772.2,
p =1 . 2×1 0
-164). The table also shows that in the NARAC
sample there are very few cases with the low-risk LL
genotype (2.25%). Because of the very small LL case
sample, we chose to use Fisher’s exact test for all
comparisons, realizing the statistic is severely conservative
when interpreted with reference to conventional alpha
levels [6]. Also, because of the small size of the LL case
sample, and because some SNPs will have dropped
genotypes, we required that at least 15 of the 18 LL cases
be genotyped. Because we categorized the high- and low-
risk subgroups according to their HLA-DRB1 genotypes, we
restrict our attention to the 21 non-chromosome 6
autosomes.
There is some evidence for population substructure in this
sample-perhaps occasioned by the fact that patients were
drawn from rheumatology clinics across North America,
while all of the controls were selected from participants
who were part of the New York Cancer Project [7]. We
searched for systematic differences in the clinical variables
that might distinguish the two case subsamples we
compared in this study. We also undertook an analysis of
substructure for the two case samples based on SNPs. We
selected every 50
th SNP from all of the autosomes, except
chromosome 6, for a sample of 9,920 SNPs, and
performed an EIGENSTRAT analysis [8].
Results
Table 2 reports the comparison of the few clinical
variables that were included with the case dataset. With
respect to sex ratio, only one of the 18 (5.6%) LL cases is
male, whereas 53 of the 163 HH cases (32.5%) are male
(p = 0.01). Despite the unequal variances, no differences
were seen in the mean values for the two continuous
clinical variables anti-cyclic citrullinated peptide (anti-
CCP) and rheumatoid factor IgM titers. Unfortunately,
no data were made available for an important beha-
vioral/environmental variable, namely smoking.
Table 3 reports the results for the two GWA analyses. The
comparison of the LL and HH cases resulted in the
identification of 17 SNPs with allele frequencies that
Table 1: Sample size for various subdivisions of the NARAC data
SS SN NN
HH HM MM HL ML LL Total
Case 163 156 15 322 125 18 799
Controls 22 34 21 249 215 652 1193
aModerate and high risk DRB1 alleles are denoted by “S” and low risk alleles by “N".
Table 2: Distribution of three clinical variables in high- and low-
risk cases
Mean (± SD)
High-risk cases Low-risk cases p-Value
Sex ratio (Male:female) 32.5% 5.6% 0.01
Anti-CCP 195.4 (246.8) 210.1 (162.4) 0.74
Rheumatoid factor 284.8 (438.1) 546.0 (927.1) 0.25
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and the LL controls resulted in the identification of
23 SNPs. Eight SNPs are common to both lists. Also
r e p o r t e di nT a b l e3a r et h em i n o ra l l e l ef r e q u e n c i e s
(MAF) in the LL cases and the frequency of the same
allele (which may be the majority allele) in the HH cases
and LL controls, as well as the closest known gene or
predicted gene.
Figure 1 plots the distribution of the LL and HH cases for
the first three principal components from the EIGEN-
STRAT analysis. Visual inspection gives no evidence that
the two groups of cases differ in any systematic fashion.
Neither does the distribution of eigenvalues. When the
low risk controls are added, however, both visual
inspection and the distribution of eigenvalues reveals
that one component is required to adjust for stratifica-
tion within the sample.
Discussion
We are, of course, aware that a sample of N = 18 cases is
extremely small by today’s standards. Nonetheless, we are
mindful that even small samples can be useful if the genetic
Table 3: Results of the GWA analyses for SNPs that differed between the comparison groups at p < 0.0001: minor allele frequency in
LL cases
SNP LL cases HH cases LL controls Physically closes gene
LL cases vs. HH cases
rs10498105
a 0.306 0.66 - EPHA4
rs2398966 0.111 0.469 - AC012154.16
rs2293004 0.361 0.699 - AADAC
rs7664880 0.361 0.704 - AC096566.2
rs1845344 0.389 0.727 - MAD2L1
rs7447161 0.083 0.396 - FER
rs1350309 0.028 0.298 - AC019176.4
rs3731239 0.333 0.687 - CDKN2A
rs10813797 0.278 0.625 - ACO1
rs7865082 0.361 0.713 - DDX58
rs2793471 0.222 0.564 - AL135933.11
rs2611279 0.111 0.426 - SLC6A15
rs7967594 0.111 0.426 - SLC6A15
rs2148443 0.139 0.497 - TMFRSF19
rs2567506 0.111 0.429 - SLC39A11
rs742605 0.111 0.436 - TRIB3
rs5771716 0.389 0.724 - FAM19A5
LL cases vs. LL cases
rs11684785 0.094 -
b 0.423 TMEM163
rs10498105 0.306 - 0.686 EPHA4
rs2398966 0.111 - 0.413 AC012154.16
rs7664880 0.361 - 0.684 AC096566.2
rs173948 0.222 - 0.548 TRIO
rs42404 0.083 - 0.386 TRIO
rs890937 0.083 - 0.377 TRIO
rs358753 0.111 - 0.421 TRIO
rs27761 0.139 - 0.452 TRIO
rs27114 0.111 - 0.442 TRIO
rs40066 0.389 - 0.707 FBXL17
rs40065 0.389 - 0.707 FBXL17
rs7447161 0.083 - 0.376 FER
rs921634 0.028 - 0.299 PKD1L1
rs1324208 0.389 - 0.719 SMARCA2
rs1396553 0.417 - 0.747 SMC3
rs2793471 0.222 - 0.584 AL135933.11
rs6539845 0.139 - 0.452 SLC6A15
rs11116408 0.139 - 0.457 SLC6A15
rs2611279 0.111 - 0.446 SLC6A15
rs7967594 0.111 - 0.447 SLC6A15
rs1380412 0.111 - 0.438 SLC6A15
rs742605 0.111 - 0.419 TRIB3
aSNPs common to both lists are boldface.
b-, not applicable.
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Woodrow [9] were able to confirm the involvement of the
MHC in type I diabetes using a sample of only 17 affected
sib-pair families. Moreover, many of the early gene
expression studies employed very small sample sizes, yet
provided useful insights into various expression patterns.
Although it is customary to report SNP allele frequencies in
terms of the MAF (as we did for the LL cases in Table 3),
our hypothesis predicts higher allele frequencies for non-
chromosome 6 susceptibility genes in RA subjects who
have LL genotypes at the HLA-DRB1 locus. For all of the
SNPs listed in Table 3, the MAF in the LL cases are less than
the comparison group. Accordingly, we would predict that
the opposite SNP allele in the LL cases is probably in
linkage disequilibrium with alleles at a functional gene.
Some of the SNPs listed in Table 3 are either in the same
gene (e.g.,TRIO, where allof the listedSNPsare intronic) or
are close to the same gene (e.g., SLC6A15 and FBXL17). We
carried out an analysis of linkage disequilibrium and
estimated the r
2 values between these adjacent SNPs from
the NARAC control panel andobtained estimatesof r
2 =1 . 0
for the two SNPs near FBXL17, r
2 = 0.384, 0.949, 0.821,
0.801, and 0.734 for the five pairs of adjacent SNPs from
TRIO (from rs173948 to rs27114), and r
2 = 0.975, 0.837,
0.997, and 0.960 for the four pairs of adjacent SNPs near
SLC6A15.
Table 4 summarizes non-chromosome 6 loci/regions that
have been identified by others as contributing to the risk of
RA. None of the SNPs identified in this study lie within
100 kb of any of these loci/regions listed in Table 4.
Conclusion
We carried out a GWA study using an extreme sampling
design on three subsets of the NARAC data. We identified
17 SNPs and 23 SNPs that distinguished the LL cases from
the HH cases, and the LL cases from the LL controls at
p < 0.0001, respectively. Eight SNPs are common to both
lists, although the presence of significant linkage disequili-
brium suggests that the actual overlap would be less. We
used a variety of sources to identify the nearest gene, or
predicted gene [15-19]. For some of these SNPs, however,
there are multiple genes in their vicinity.
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Table 4: Previously identified non-chromosome 6 loci or regions that contribute to the risk of RA
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PTPN22 1p13 Non-synonymous coding SNP Begovich et al. [12]
MHC2TA 16p13 SNP in the type III of the MHC class II transactivator Swanberg et al. [13]
STAT4 2q32.2-3 Intronic SNP Remmers et al. [14]
TRAF1-C5 9q33-34 A 100-kb region Plenge et al. [7]
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